Press Releases

The Board of Active Biotech AB proposes that the Annual General Meeting resolve to make a guaranteed rights issue of approximately SEK 256 M
April 6, 2009 08:31 (CEST)
Notice of Annual General Meeting of Shareholders
April 6, 2009 08:30 (CEST)
ORAL LAQUINIMOD FOR MULTIPLE SCLEROSIS GRANTED FAST TRACK STATUS BY FDA
February 12, 2009 17:28 (CET)
Active Biotech AB year End Report January-December 2008
February 12, 2009 08:30 (CET)
Information from Active Biotech AB's Election Committee
January 26, 2009 10:30 (CET)
Active Biotech's Cancer Project ANYARA: Combination with Established Tumor Therapies Promising
December 10, 2008 08:30 (CET)
Active Biotech's election committee appointed
November 28, 2008 10:30 (CET)
Teva Completes Enrollment in Laquinimod Phase III Clinical Trial
November 18, 2008 08:00 (CET)
Active Biotech AB Interim Report January-September 2008
November 14, 2008 08:30 (CET)
Active Biotech to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
November 6, 2008 08:30 (CET)